HIF1A and sarcoma: We next sought to (1) confirm that metronomic doxorubicin has similar effects on HT1080 xenografts as HIF-1α knockdown, (2) examine multimodal therapy in a third sarcoma mouse model, SK-LMS-1 human leiomyosarcoma xenografts, and (3) examine the effects of multimodal therapy on DNA damage.